Toxicological considerations for antithyroid drugs in children

Bibliography

• Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005;7:515-21
   Google Scholar
• Davies TF, Larsen PR. Thyrotoxicosis. In: Williams' textbook of endocrinology. Larsen PR, Kronenberg HM, Melmed S, editors. 10th edition. WB Saunders Co, Philadelphia; 2003. p. 374-422
   Google Scholar
• Turnbridge WMG, Evered DC, Hall R. The spectrum of thyroid disease in a community. Clin Endocrinol (Oxf) 1977;7:483-93
   Google Scholar
• Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;7:109-25
   Google Scholar
• Foley TP. Thyrotoxicosis in childhood. Pediatr Ann 1992;21:43-9
   PubMed Web of Science ®Google Scholar
• Lavard L, Ranlov I, Perrild H, Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol 1994;130:565-8
   PubMed Web of Science ®Google Scholar
• Kraiem Z, Newfield RS. Graves' disease in childhood. J Pediatr Endocrinol Metab 2001;14:229-43
   PubMed Web of Science ®Google Scholar
• Segni M, Gorman CA. The aftermath of childhood hyperthyroidism. J Pediatr Endocrinol Metab 2001;14(Suppl 5):1277-82
   PubMedGoogle Scholar
• Kaguelidou F, Alberti C, Castanet M, ; French Childhood Graves' Disease Study Group. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817-26
   PubMed Web of Science ®Google Scholar
• Wong GW, Cheng PS. Increasing incidence of childhood Graves' disease in Hong Kong: a follow-up study. Clin Endocrinol (Oxf) 2001;54:547-50
   PubMed Web of Science ®Google Scholar
• Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24
   PubMed Web of Science ®Google Scholar
• Lazar L, Kalter-Leibovici O, Pertzelan A, Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-82
   PubMed Web of Science ®Google Scholar
• Kaguelidou F, Carel JC, Leger J. Graves' disease in childhood: advances in management with antithyroid drug therapy. Horm Res 2009;71:310-17
   PubMed Web of Science ®Google Scholar
• Rivkees SA. Pediatric graves' disease: controversies in management. Horm Res Paediatr 2010;74:305-11
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17
   PubMed Web of Science ®Google Scholar
• Mackenzie CG. Differentiation of the antithyroid drug thioracil and paba from sulfonamides by iodide administration. Endocrinology 1947;40:137-53
   PubMed Web of Science ®Google Scholar
• Astwood EB. Chemotherapy of hyperthyroidism. Harvey Lect 1945;40:195-235
   Web of Science ®Google Scholar
• Lawson A, Barry G. Treatment of thyrotoxicosis with 2-carbethoxythio-1methylglyoxaline. Lancet 1951;2:621
   PubMedGoogle Scholar
• Janson R, Dahlberg PA, Lindstrom B. Comparative bioavaibility of carbimazole and methimazole. Int J Clin Pharamcol Ther Toxicol 1983;21:505-10
   PubMedGoogle Scholar
• Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 2010;95:2227-33
   PubMed Web of Science ®Google Scholar
• Hoffman WH, Miceli JN. Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. Dev Pharmacol Ther 1988;11:73-81
   PubMedGoogle Scholar
• Ringhand HP, Ritschel WA, Meyer MC, Bioavailability of propylthiouracil in humans. J Pharm Sci 1983;72:1409-12
   PubMed Web of Science ®Google Scholar
• Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodmans and gilmans: the pharmacological basis of therapeutics. 10th edition, Mc Graw Hill, USA; 2001. p. 1563-96
   Google Scholar
• Skellern GG, Knight BI, Low CK, The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. J Clin Pharmac 1980;9:137-43
   Web of Science ®Google Scholar
• Okuno A, Taguchi T, Inyaku F, Pharmakokinetics of propylthiouracil in children and adolescents with Graves' disease after a single oral dose. Pediatr Pharmacol (New York) 1983;3:43-4
   PubMedGoogle Scholar
• Okuno A, Yano K, Inyaku F, Pharmakokinetics of methimazole in children and adolescents with Graves' disease. Studies on plasma and intrathyroidal concentrations. Acta Endocrinol (Copenh) 1987;115:122-8
   Google Scholar
• McCruden DC, Hilditch TE, Conell JMC, Duration of antithyroid action of methimazole estimated by an intravenous perchlorate discharge test. Clin Endocrinol (Oxf) 1987;26:33-9
   PubMed Web of Science ®Google Scholar
• Taurog A, Dorris ML. Propylthiouracil and methimazole display contrasting pathways of peripheral metabolism in both rat and human. Endocrinology 1988;122:592-601
   PubMed Web of Science ®Google Scholar
• Boyer JL. Changing concepts on the mechanisms of hepatic drug toxicity. Minutes of the hepatic toxicity following treatment for pediatric Graves' disease meeting of Eunice Kennedy Shriver National Institute of Child Health and Human Development, 28th of October 2008. p. 18-20. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/upload/Hepatic-Toxicity-10-28-08-final-final-01-09-09.pdf [Last assessed 31 January 2011]
   Google Scholar
• Vickers AE, Fisher RL, Sinclair JR. Glutathione modulation and oxidative stress in human liver slices. Curr Drug Discov Technol 2010;7:154-69
   PubMedGoogle Scholar
• Twele R, Kern W, Spiteller G. 2-mercapto-1-methyl-5-methyl-mercaptoimidazole: a new metabolite of thiamazole. Xenobiotica 1983;13:661-8
   PubMed Web of Science ®Google Scholar
• Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343:118-26
   PubMed Web of Science ®Google Scholar
• Gardner DF, Cruikshank DP, Hays PM, Cooper DS. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab 1986;62:217-20
   PubMed Web of Science ®Google Scholar
• Mortimer RH, Cannell GR, Addison RS, Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997;82:3099-102
   PubMed Web of Science ®Google Scholar
• Rivkees SA. Treatment of hyperthyroidism due to Grave's disease in children. In: Krassas GE, Rivkees SA, Kiess W, editors. Diseases of the thyroid in childhood and adolescence. In: pediatric and adolescent medicine, Kiess W, Branski D, editors. (Volume 11). Karger; 2007. p. 169-91
   Google Scholar
• Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 1993;76:1516-21
   PubMed Web of Science ®Google Scholar
• Homsanit M, Sriussadaporn S, Vannasaeng S, Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001;54:385-90
   PubMed Web of Science ®Google Scholar
• Nakamura H, Noh JY, Itoh K, Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2007;92:2157-62
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-76
   PubMed Web of Science ®Google Scholar
• Ginsberg G, Hattis D, Miller R, Sonawane B. Pediatric pharmakokinetic data: Implications for envriromental risk assessment for children. Pediatrics 2004;113:973-83
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kida I, Wada H. A volumetric analysis of the brain and hippocampus of rats rendered perinatal hypothyroid. Neurosci Lett 2010. [Epub ahead of print]
   Google Scholar
• Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702-55
   PubMed Web of Science ®Google Scholar
• Anselmo J, Cao D, Karrison T, Fetal loss associated with excess of thyroid hormone exposure. JAMA 2004;292:691-5
   PubMed Web of Science ®Google Scholar
• Millar LK, Wing DA, Leung AS, Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994;84:946-9
   PubMed Web of Science ®Google Scholar
• Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf) 2001;54:365-70
   PubMed Web of Science ®Google Scholar
• Cheron RG, Kaplan MM, Larsen PR, Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N Engl J Med 1981;304:525-8
   PubMed Web of Science ®Google Scholar
• Gardner DF, Cruikshank DP, Hays PM, Cooper DS. Pharmacology of propylthiouracil (PTU) in pregnant hyperthyroid women: correlation of maternal PTU concentrations with cord serum thyroid function tests. J Clin Endocrinol Metab 1986;62:217-20
   PubMed Web of Science ®Google Scholar
• Momotani N, Noh J, Oyanagi H, Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 1986;315:24-8
   PubMed Web of Science ®Google Scholar
• Harper L, Chin L, Daykin J, Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (Oxf) 2004;60:671-5
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen M, Ye H, Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxf) 2008;47:1515-20
   PubMed Web of Science ®Google Scholar
• Sato H, Hattori M, Fujieda M, High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-3
   PubMed Web of Science ®Google Scholar
• Clementi M, Gianatonio E, Pelo E, Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999;83:43-6
   PubMed Web of Science ®Google Scholar
• Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994;4:129-33
   PubMed Web of Science ®Google Scholar
• Foulds N, Walpole I, Elmsile F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet 2005;132A:130-5
   PubMed Web of Science ®Google Scholar
• Ramirez A, Espinosa de los Monteros A, Parra A, De Leon B. Esophageal atresia and tracheoesophageal fistula in two infants born to hyperthyroid women receiving methimazole (Tapazol) during pregnancy. Am J Med Genet 1992;44:200-2
   PubMed Web of Science ®Google Scholar
• Seoud M, Nassar A, Usta I, Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. Am J Perinatol 2003;20:59-62
   PubMed Web of Science ®Google Scholar
• Barbero P, Valdez R, Rodriguez H, Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet A 2008;146A:2390-5
   PubMed Web of Science ®Google Scholar
• Momotani N, Ito K, Hamada N, Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf) 1984;20:695-700
   PubMed Web of Science ®Google Scholar
• Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 1987;106:60-1
   PubMed Web of Science ®Google Scholar
• Martinez-Frias ML, Cereijo A, Rodriguez-Pinilla E, Methimazole in animal feed and congenital aplasia cutis. Lancet 1992;339:742-3
   PubMed Web of Science ®Google Scholar
• Vogt T, Stolz W, Landthaler M. Aplasia cutis congenita after exposure to methimazole: a causal relationship? Br J Dermatol 1995;133:994-6
   PubMed Web of Science ®Google Scholar
• Wilson LC, Kerr BA, Wilkinson R, Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet 1998;75:220-2
   PubMed Web of Science ®Google Scholar
• Abe M, Syuto T, Yokoyama Y, Ishikawa O. Aplasia cutis congenita after methimazole exposure in utero successfully treated with basic fibroblast growth factor. Int J Dermatol 2010;49:334-5
   PubMed Web of Science ®Google Scholar
• Valdez RM, Barbero PM, Liascovich RC, Methimazole embryopathy: a contribution to defining the phenotype.. Reprod Toxicol 2007;23:253-5
   PubMed Web of Science ®Google Scholar
• Messer PM, Hauffa BP, Olbricht T, Antithyroid drug treatment of Graves' disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990;123:311-16
   PubMedGoogle Scholar
• Eisenstein Z, Weiss M, Katz Y, Bank H. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr 1992;151:558-9
   PubMed Web of Science ®Google Scholar
• Wolf D, Foulds N, Daya H. Antenatal carbimazole and choanal atresia: a new embryopathy. Arch Otolaryngol Head Neck Surg 2006;132:1009-11
   PubMed Web of Science ®Google Scholar
• Guignon AM, Mallaret MP, Jouk PS. Carbimazole-related gastroschisis. Ann Pharmacother 2003;37:829-31
   PubMed Web of Science ®Google Scholar
• Johnson KA, Weber PA, Jones KL, Chambers CD. Selection bias in Teratology Information Service pregnancy outcome studies. Teratology 2001;64:79-82
   PubMedGoogle Scholar
• Hancock RL, Koren G, Einarson A, Ungar WJ. The effectiveness of teratology information services (TIS). Reprod Toxicol 2007;23:125-32
   PubMed Web of Science ®Google Scholar
• Di Gianantonio E, Schaefer C, Mastroiacovo PP, Adverse effects of prenatal methimazole exposure. Teratology 2001;64:262-6
   PubMedGoogle Scholar
• Clementi M, Di Gianantonio E, Cassina M, ; the SAFE-Med Study Group. Treatment of Hyperthyroidism in Pregnancy and Birth Defects. J Clin Endocrinol Metab 2010;95:E337-41
   PubMed Web of Science ®Google Scholar
• Rosenfeld H, Ornoy A, Shechtman S, Diav-Citrin O. Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: a controlled cohort study. Br J Clin Pharmacol 2009;68:609-17
   PubMed Web of Science ®Google Scholar
• Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. Ann Pharmacother 2007;41:1018-22
   PubMed Web of Science ®Google Scholar
• McDougall IR, Bayer MF. Should a woman taking propylthiouracil breast-feed? Clin Nucl Med 1986;11:249-50
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs: to breast-feed or not to breast-feed. Am J Obstet Gynecol 1987;157:234-5
   PubMed Web of Science ®Google Scholar
• Goldman JM. Propylthiouracil and breast-feeding. CMAJ 1987;137:701-2
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 1989;84:924-36
   PubMed Web of Science ®Google Scholar
• Lee A, Moretti ME, Collantes A, Choice of breastfeeding and physicians' advice: a cohort study of women receiving propylthiouracil. Pediatrics 2000;106(Pt 1):27-30
   PubMed Web of Science ®Google Scholar
• Rylance GW, Woods CG, Donnelly MC, Carbimazole and breastfeeding. Lancet 1987;1:928
   PubMed Web of Science ®Google Scholar
• Azizi F. Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants. J Pediatr 1996;128:855-8
   PubMed Web of Science ®Google Scholar
• Azizi F. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. J Endocrinol Invest 2003;26:301-4
   PubMed Web of Science ®Google Scholar
• Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 2000;85:3233-8
   PubMed Web of Science ®Google Scholar
• Azizi F, Bahrainian M, Khamseh ME, Khoshniat M. Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. Pediatr Endocrinol Metab 2003;16:1239-43
   PubMed Web of Science ®Google Scholar
• Mizuno H, Sugiyama Y, Nishi Y, Elevation of serum creatine kinase in response to medical treatment of Graves' disease in children. Acta Paediatr 2006;95:243-5
   PubMed Web of Science ®Google Scholar
• Moore FD. Toxic manifestations of thiouracil therapy. JAMA 1946;130:315-19
   PubMed Web of Science ®Google Scholar
• Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995;80:1083-5
   PubMed Web of Science ®Google Scholar
• Williams KV, Nayak S, Becker D, Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-33
   PubMed Web of Science ®Google Scholar
• Ruiz JK, Rossi GV, Vallejos HA, Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003;37:224-8
   PubMed Web of Science ®Google Scholar
• Eunice Kennedy Shriver National Institute of Child Health and Human Development. Minutes of the hepatic toxicity following treatment for pediatric Graves' disease meeting. 28th of October 2008; p. 1-26. Available from: http://bpca.nichd.nih.gov/collaborativeefforts/upload/Hepatic-Toxicity-10-28-08-final-final-01-09-09.pdf [Last assessed 31 January 2011]
   Google Scholar
• Livadas S, Xyrafis X, Economou F, Liver failure due to antithyroid drugs: report of a case and literature review. Endocrine 2010;38:24-8
   PubMed Web of Science ®Google Scholar
• Karras S, Tzotzas T, Krassas GE. Antithyroid drugs used in the treatment of hyperthyroidism during breastfeeding: an update and new perspectives. Hormones (Athens) 2009;8:254-7
   PubMedGoogle Scholar
• Karras S, Tzotzas T, Kaltsas T, Krassas GE. Pharmacological treatment of hyperthyroidism during lactation: review of the literature and novel data. Pediatr Endocrinol Rev 2010;8:25-33
   PubMedGoogle Scholar
• Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-5
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Mattison DR. Propylthiouracil (PTU)-induced liver failure and recommendations for the discontinuation of PTU use in children. Int J Pediatr Endocrinol 2009;2009:132041
   PubMedGoogle Scholar
• Bahn RS, Burch HS, Cooper DS, The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009;19:673-4
   PubMedGoogle Scholar
• Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole on children. J Clin Endocrinol Metab 2010;95:3260-7
   PubMed Web of Science ®Google Scholar
• Safety alerts for human medical products: propylthiouracil 2010. FDA US Food and Drug Administration, 2010 Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm164162htm [Last assessed 10 November 2010]
   Google Scholar
• Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves' disease in children. Int J Pediatr Endocrinol 2010;2010:176970
   PubMedGoogle Scholar
• Wall JR, Fang SL, Kuroki T, In vitro immunoreactivity to propylthiouracil, methimazole and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 1984;58:868-72
   PubMed Web of Science ®Google Scholar
• Vogt BA, Kim Y, Jenette JC, Antineutrophil autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8
   PubMed Web of Science ®Google Scholar
• Fujieda M, Nagata M, Akioka Y, Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy. Acta Pediatr Jpn 1998;40:286-9
   PubMedGoogle Scholar
• Poomthavorn P, Mahachoklertwattana P, Tapaneya-Olarn W, Antineutrophil cytoplasmic antibody-positive systemic vasculitis associated with Propylthiouracil therapy:report of 2 children with Graves disease. J Med Assoc Thai 2002;85(Suppl 4):s1295-301
   PubMedGoogle Scholar
• Panamonta O, Sumethkul V, Radinahmed P, Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves' disease. J Pediatr Endocrinol Metab 2008;21:539-43
   PubMed Web of Science ®Google Scholar